Funding for this research was provided by:
Health Research Fund of Central Denmark Region (no reference number)
Health Foundation (15-B-0160)
LSB Foundation (no ref.no. was provided)
Familien Hede Nielsens Fond (no ref.no. was provided)
KV Fonden (no ref.no. was provided)
Aragon Foundation (no ref.no. was provided)
Received: 16 July 2020
Accepted: 24 November 2020
First Online: 4 December 2020
Ethics approval and consent to participate
: The study was approved by the local Ethical Committee of the Central Denmark Region (journal no.: 1–16–02-209-15) and by the Danish Data Protection Agency (journal no.: 1–10–72-69-15). Further, all women provided their written informed consent to participate in the study.
: Not applicable.
: Axlab, the Danish manufacturer of the Evalyn® Brush, provided self-sampling devices for the study. In accordance with the contract between the manufacturers and the Department of Public Health Programmes, Randers Regional Hospital, Axlab had no influence on the scientific process and no editorial rights pertaining to this manuscript. The authors retained the right to submit the manuscript. None of the authors were compensated for their work on this study, have any shares in the manufacturers’ companies, or received bonuses from any of the manufacturers. MT, JSJ, BHB, and BA have participated in other studies with HPV test kits sponsored by Roche and self-sampling devices sponsored by Axlab. MT has received honoraria from Roche Diagnostics and AstraZeneca for lectures on HPV self-sampling and HPV triage-methods. The authors declare no conflicts of interest.